To further investigate a still-prevailing deficit of TGFα, we assessed TGFα levels in cerebrospinal fluid (CSF) samples obtained from treatment-naïve patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) and controls with non-inflammatory disease. Here, TGFA is linked to relapsing-remitting multiple sclerosis.